– Abstract on data from a two-part phase 1c,
multiple ascending dose study accepted for oral presentation
–
– New data highlighting the Company's lead
drug candidate ZT002 for obesity –
BEIJING, Sept. 3,
2024 /PRNewswire/ -- Beijing QL Biopharmaceutical
Co., Ltd. ("QL Biopharm"), a clinical stage biopharmaceutical
company developing innovative biologic drugs for the treatment of
metabolic diseases, today announces that an abstract on its lead
drug candidate ZT002 will be presented at the European Association
for the Study of Diabetes (EASD) Annual Meeting 2024, Madrid, Spain on Thursday 12 September 2024.
QL Biopharm's lead asset, ZT002 is a novel ultra long-acting
glucagon-like peptide-1 receptor agonist ("GLP-1 RA") in
development for obesity with monthly subcutaneous administration.
The phase 1c, randomized, placebo-controlled, double-blind multiple
ascending dose study was conducted in 28 patients with obesity.
Patients were randomly assigned to receive either ZT002 or placebo.
Results from the study showed that ZT002 had a favorable safety and
tolerability profile. Further, ZT002 induced clinically meaningful
weight loss with associated cardiometabolic improvements.
Dr. Zhang Xujia, Ph.D., Founder, Chairman and Chief Executive
Officer of QL Biopharm said: "The emerging profile of ZT002
holds great promise as a new standard of care for patients living
with obesity. The safety and tolerability seen in patients
receiving ZT002 is aligned with the GLP-1RA class. ZT002 has the
potential to simplify obesity treatment. We look forward to
advancing our ongoing studies and further exploring the potential
of ZT002 for weight management and type 2 diabetes
treatment."
Details of the EASD Annual Meeting 2024 poster presentation
are as follows:
Title: ZT002, a novel ultra long-acting glp-1
receptor agonist in adults with overweight or obesity: a
randomized, placebo-controlled, multiple ascending dose phase 1c
study
Session: OP 25 Incretin receptor agonists: better
and better
Date and Time: Thursday, 12
September 2024, 11:15 - 11:30
CEST
Presenter: Linong Ji, MD, Professor of Medicine at
Peking University People's Hospital
Location: Madrid Hall
Abstract Number: 147
For more information about the EASD Annual Meeting 2024,
including details related to accepted abstracts and presentations,
please visit its website. The Abstract is available on the EASD
online planner here.
NOTES TO EDITORS
About QL Biopharm
QL Biopharm is a clinical-stage biopharmaceutical company
focused on developing novel best-in-class peptide therapeutics for
metabolic diseases. The Company leverages its proprietary E.
coli manufacturing process enabling rapid and cost-effective
scaling of manufacturing for high volume markets. The lead drug
candidate, ZT002, is an ultra long-acting subcutaneously
administered GLP-1 receptor agonist, currently in a Phase 2 study
for obesity and in Phase 1 for type 2 diabetes. In Phase 1 studies,
ZT002 demonstrated compelling weight loss and tolerability
consistent with the GLP-1 RA class. The Company is also advancing a
broader portfolio of novel preclinical assets for the treatment of
metabolic diseases, in addition to its biosimilar semaglutide
program, currently in Phase 3. QL Biopharm is led by a team of
pharma industry veterans with expertise in E. coli–based
peptide manufacturing and the development of drugs for metabolic
diseases. The Company is backed by leading professional life
science investors.
For additional information, please visit
https://qlbiopharm.com/
About EASD
The European Association for the Study of Diabetes e.V. (EASD)
is a membership-based academic non-profit organization. It was
founded in 1965 and its headquarters is based in Duesseldorf, Germany. The aims of the
Association are to encourage and support research in the field of
diabetes, the rapid diffusion of acquired knowledge and to
facilitate its application.
View original
content:https://www.prnewswire.com/news-releases/ql-biopharm-announces-abstract-on-novel-ultra-long-acting-glp-1ra-to-be-presented-at-easd-annual-meeting-2024-302236189.html
SOURCE Beijing QL Biopharmaceutical Co., Ltd.